A Neuronal Isoform of Nitric Oxide Synthase Expressed in Pancreatic β-Cells Controls Insulin Secretion
- Anne-Dominique Lajoix1,
- Hubbert Reggio2,
- Thierry Chardès14,
- Sylvie Péraldi-Roux1,
- Florence Tribillac3,
- Michèle Roye1,
- Samuel Dietz1,
- Christophe Broca1,
- Michèle Manteghetti1,
- Gérard Ribes1,
- Claes B. Wollheim5 and
- René Gross1
- 1Unité mixte de recherche 5094 du Centre National de la Recherche Scientifique (CNRS), Université Montpellier I
- 2UMR 5539 du CNRS, Université Montpellier II
- 3Centre Régional d’Imagerie Cellulaire, Institut Universitaire de Recherche Clinique, Montpellier
- 4Unité mixte de recherche de l’Institut National de la Recherche Agronomique et du CNRS 5087, Laboratoire de Pathologie Comparée, Saint Christol-les-Alès, France
- 5Division de Biochimie Clinique, Department of Internal Medecine, University Medical Center, Geneva, Switzerland
Abstract
Evidence is presented showing that a neuronal isoform of nitric oxide synthase (NOS) is expressed in rat pancreatic islets and INS-1 cells. Sequencing of the coding region indicated a 99.8% homology with rat neuronal NOS (nNOS) with four mutations, three of them resulting in modifications of the amino acid sequence. Double-immunofluorescence studies demonstrated the presence of nNOS in insulin-secreting β-cells. Electron microscopy studies showed that nNOS was mainly localized in insulin secretory granules and to a lesser extent in the mitochondria and the nucleus. We also studied the mechanism involved in the dysfunction of the β-cell response to arginine and glucose after nNOS blockade with NG-nitro-l-arginine methyl ester. Our data show that miconazole, an inhibitor of nNOS cytochrome c reductase activity, either alone for the experiments with arginine or combined with sodium nitroprusside for glucose, is able to restore normal secretory patterns in response to the two secretagogues. Furthermore, these results were corroborated by the demonstration of a direct enzyme-substrate interaction between nNOS and cytochrome c, which is strongly reinforced in the presence of the NOS inhibitor. Thus, we provide immunochemical and pharmacological evidence that β-cell nNOS exerts, like brain nNOS, two catalytic activities: a nitric oxide production and an NOS nonoxidating reductase activity, both of which are essential for normal β-cell function. In conclusion, we suggest that an imbalance between these activities might be implicated in β-cell dysregulation involved in certain pathological hyperinsulinic states.
Footnotes
-
Address correspondence and reprint requests to René Gross, Institut de Biologie, Laboratoire de Pharmacologie, Boulevard Henri IV, 34060 Montpellier Cedex 1, France. E-mail: gross{at}zeus.sc.univ-montp1.fr.
Received for publication 28 January 2000 and accepted in revised form 15 March 2001.
AUC, area under the curve; BSA, bovine serum albumin; eNOS, endothelial NOS; FITC, fluorescein isothyocyanate; iNOS, inducible NOS; KATP, ATP-dependent K+ channel; l-NAME, NG-nitro-l-arginine methyl ester; NADPH-d, NADPH-diaphorase; NO, nitric oxide; NOS, NO synthase; nNOS, neuronal NOS; PBS, phosphate-buffered saline; PBS-T, PBS containing 0.1% Tween 20; PCR, polymerase chain reaction; RT, reverse transcription; SNP, sodium nitroprusside; TCA, tricarboxylic acid.














